Blocking α v β 3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Maile, Laura A ^a,b   Gollahon, Katherine ^a   Wai, Christine ^a   Dunbar, Paul ^a   Busby, Walker ^a   Clemmons, David ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Vascular Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBODY; BETA3 INTEGRIN ANTIBODY; CREATININE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; BIOLOGICAL MARKER; COLLAGEN TYPE 4; LIGAND; MEMBRANE PROTEIN; NEPHRIN; PROTEIN BINDING; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HUMAN CELL; KIDNEY FUNCTION; MALE; NONHUMAN; PHOSPHORYLATION; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; URINE;

ALBUMINURIA; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLLAGEN TYPE IV; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; INTEGRIN ALPHAVBETA3; KIDNEY; LIGANDS; MALE; MEMBRANE PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84911127140     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/421827     Document Type: Article

References (44)

1. Kanwar Y. S., Sun L., Xie P., Liu F.-Y., Chen S., A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annual Review of Pathology: Mechanisms of Disease 2011 6 395 423 10.1146/annurev.pathol.4.110807.092150 2-s2.0-79751477368
2. Turgut F., Bolton W. K., Potential new therapeutic agents for diabetic kidney disease. The American Journal of Kidney Diseases 2010 55 5 928 940 10.1053/j.ajkd.2009.11.021 2-s2.0-77951622247
3. Nawroth P. P., Isermann B., Mechanisms of diabetic nephropathy-old buddies and newcomers part 1. Experimental and Clinical Endocrinology and Diabetes 2010 118 9 571 576 10.1055/s-0030-1255051 2-s2.0-77958114639
4. Thomas M. C., Groop P.-H., New approaches to the treatment of nephropathy in diabetes. Expert Opinion on Investigational Drugs 2011 20 8 1057 1071 10.1517/13543784.2011.591785 2-s2.0-79960371057
5. Shepler B., Nash C., Smith C., DiMarco A., Petty J., Szewciw S., Update on potential drugs for the treatment of diabetic kidney disease. Clinical Therapeutics 2012 34 6 1237 1246 10.1016/j.clinthera.2012.04.026 2-s2.0-84862118638
6. Advani A., Gilbert R. E., The endothelium in diabetic nephropathy. Seminars in Nephrology 2012 32 2 199 207 10.1016/j.semnephrol.2012.02.006 2-s2.0-84862095356
7. Nakagawa T., Tanabe K., Croker B. P., Johnson R. J., Grant M. B., Kosugi T., Li Q., Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nature Reviews Nephrology 2011 7 1 36 44 10.1038/nrneph.2010.152 2-s2.0-78650522881
8. Kolluru G. K., Bir S. C., Kevil C. G., Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. International Journal of Vascular Medicine 2012 2012 30 918267 10.1155/2012/918267 2-s2.0-84862182412
9. Diez-Sampedro A., Lenz O., Fornoni A., Podocytopathy in diabetes: a metabolic and endocrine disorder. American Journal of Kidney Diseases 2011 58 4 637 646 10.1053/j.ajkd.2011.03.035 2-s2.0-80053052721
10. Hamerski D. A., Santoro S. A., Integrins and the kidney: biology and pathobiology. Current Opinion in Nephrology and Hypertension 1999 8 1 9 14 10.1097/00041552-199901000-00003 2-s2.0-0032915892
11. Dentelli P., Rosso A., Zeoli A., Gambino R., Pegoraro L., Pagano G., Falcioni R., Brizzi M. F., Oxidative stress-mediated mesangial cell proliferation requires RAC-1/reactive oxygen species production and β 4 integrin expression. The Journal of Biological Chemistry 2007 282 36 26101 26110 10.1074/jbc.M703132200 2-s2.0-34548861472
12. Pedchenko V. K., Chetyrkin S. V., Chuang P., Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005 54 10 2952 2960 10.2337/diabetes.54.10.2952 2-s2.0-25844476029
13. Jin D. K., Fish A. J., Wayner E. A., Mauer M., Setty S., Tsilibary E., Kim Y., Distribution of integrin subunits in human diabetic kidneys. Journal of the American Society of Nephrology 1996 7 12 2636 2645 2-s2.0-9844241050
14. Nicholas S. B., Liu J., Kim J., Ren Y., Collins A. R., Nguyen L., Hsueh W. A., Critical role for osteopontin in diabetic nephropathy. Kidney International 2010 77 7 588 600 10.1038/ki.2009.518 2-s2.0-77949540507
15. Lu A., Miao M., Schoeb T. R., Agarwal A., Murphy-Ullrich J. E., Blockade of TSP1-dependent TGF- β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. American Journal of Pathology 2011 178 6 2573 2586 10.1016/j.ajpath.2011.02.039 2-s2.0-79959473807
16. Li R., Ren M., Chen N., Luo M., Zhang Z., Wu J., Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. PLoS ONE 2012 7 5 e37195 10.1371/journal.pone.0037195 2-s2.0-84861013031
17. Miller E. C., Capps B. E., Sanghani R. R., Clemmons D. R., Maile L. A., Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia. Investigative Ophthalmology & Visual Science 2007 48 8 3878 3887 10.1167/iovs.07-0014 2-s2.0-34648828684
18. Maile L. A., Capps B. E., Ling Y., Xi G., Clemmons D. R., Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology 2007 148 5 2435 2443 10.1210/en.2006-1440 2-s2.0-34249794018
19. V β 3 integrin inhibits development of atherosclerotic lesions in diabetic pigs. Science Translational Medicine 2010 2 18 18ra11 10.1126/scitranslmed.3000476 2-s2.0-77953073611
20. Maile L. A., Badley-Clarke J., Clemmons D. R., Structural analysis of the role β 3 subunit of the α V β 3 integrin in IGF-I signaling. Journal of Cell Science 2001 114 7 1417 1425 2-s2.0-0035035159
21. Turgut F., Bolton W. K., Potential new therapeutic agents for diabetic kidney disease. American Journal of Kidney Diseases 2010 55 5 928 940 10.1053/j.ajkd.2009.11.021 2-s2.0-77951622247
22. Thomas M. C., Groop P. H., New approaches to the treatment of nephropathy in diabetes. Expert Opinion on Investigational Drugs 2011 20 8 1057 1071 10.1517/13543784.2011.591785 2-s2.0-79960371057
23. McGregor B., Colon S., Mutin M., Chignier E., Zech P., McGregor J., Thrombospondin in human glomerulopathies: a marker of inflammation and early fibrosis. The American Journal of Pathology 1994 144 6 1281 1287 2-s2.0-0028270932
24. Turk T., Leeuwis J. W., Gray J., Torti S. V., Lyons K. M., Nguyen T. Q., Goldschmeding R., BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. Journal of Histochemistry and Cytochemistry 2009 57 7 623 631 10.1369/jhc.2009.953224 2-s2.0-67651149607
25. Jim B., Ghanta M., Qipo A., Fan Y., Chuang P. Y., Cohen H. W., Abadi M., Thomas D. B., He J. C., Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS ONE 2012 7 5 e36041 10.1371/journal.pone.0036041 2-s2.0-84861211354
26. Cohen-Bucay A., Viswanathan G., Urinary markers of glomerular injury in diabetic nephropathy. International Journal of Nephrology 2012 2012 11 146987 10.1155/2012/146987 2-s2.0-84866252514
27. Oriente F., Iovino S., Cassese A., Romano C., Miele C., Troncone G., Balletta M., Perfetti A., Santulli G., Iaccarino G., Valentino R., Beguinot F., Formisano P., Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C- β activity and TGF- β 1 expression. Diabetologia 2009 52 12 2642 2652 10.1007/s00125-009-1528-z 2-s2.0-70949083239
28. Pedchenko V. K., Chetyrkin S. V., Chuang P., Ham A.-J. L., Saleem M. A., Mathieson P. W., Hudson B. G., Voziyan P. A., Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005 54 10 2952 2960 10.2337/diabetes.54.10.2952 2-s2.0-25844476029
29. Nicholas S. B., Liu J., Kim J., Critical role for osteopontin in diabetic nephropathy. Kidney International 2010 77 7 588 600 10.1038/ki.2009.518 2-s2.0-77949540507
30. Wang S., Wu X., Lincoln T. M., Murphy-Ullrich J. E., Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF- β activity. Diabetes 2003 52 8 2144 2150 10.2337/diabetes.52.8.2144 2-s2.0-0043268713
31. 184 sequence of the β 3-subunit of α V β 3. Molecular Endocrinology 2006 20 2 405 413 10.1210/me.2005-0241 2-s2.0-31444448603
32. Maile L. A., Gollahon K., Wai C., Byfield G., Hartnett M. E., Clemmons D., Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes. Diabetologia 2012 55 3 835 844 10.1007/s00125-011-2416-x 2-s2.0-84856717783
33. Nakagawa T., Kosugi T., Haneda M., Rivard C. J., Long D. A., Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009 58 7 1471 1478 10.2337/db09-0119 2-s2.0-67650236579
34. Yamamoto Y., Maeshima Y., Kitayama H., Kitamura S., Takazawa Y., Sugiyama H., Yamasaki Y., Makino H., Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004 53 7 1831 1840 10.2337/diabetes.53.7.1831 2-s2.0-3042739353
35. Ichinose K., Maeshima Y., Yamamoto Y., Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005 54 2891 2903
36. Zhang S. X., Wang J. J., Lu K., Mott R., Longeras R., Ma J. X., Therapeutic potential of angiostatin in diabetic nephropathy. Journal of the American Society of Nephrology 2006 17 2 475 486 10.1681/ASN.2005020217 2-s2.0-33645456579
37. Ichinose K., Maeshima Y., Yamamoto Y., Kinomura M., Hirokoshi K., Kitayama H., Takazawa Y., Sugiyama H., Yamasaki Y., Agata N., Makino H., 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 2006 55 5 1232 1242 10.2337/diabetes. 2-s2.0-33745299881
38. Nasu T., Maeshima Y., Kinomura M., Hirokoshi-Kawahara K., Tanabe K., Sugiyama H., Sonoda H., Sato Y., Makino H., Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 2009 58 10 2365 2375 10.2337/db08-1790 2-s2.0-70349636755
39. Saito D., Maeshima Y., Nasu T., Yamasaki H., Abe K., Sugiyama H., Sonoda H., Sato Y., Makino H., Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. The American Journal of Physiology-Renal Physiology 2011 300 4 F873 F886 10.1152/ajprenal.00503.2010 2-s2.0-79954466760
40. 3 integrin antagonist RGDechiHCit. Journal of Translational Medicine 2011 9, article 7 10.1186/1479-5876-9-7 2-s2.0-78651314991
41. Wei C., Moller C. C., Altintas M. M., Li J., Schwarz K., Zacchigna S., Xie L., Henger A., Schmid H., Rastaldi M. P., Cowan P., Kretzler M., Parrilla R., Bendayan M., Gupta V., Nikolic B., Kalluri R., Carmeliet P., Mundel P., Reiser J., Modification of kidney barrier function by the urokinase receptor. Nature Medicine 2008 14 1 55 63 10.1038/nm1696 2-s2.0-38049032013
42. Brosius F. C. III, Alpers C. E., Bottinger E. P., Breyer M. D., Coffman T. M., Gurley S. B., Harris R. C., Kakoki M., Kretzler M., Leiter E. H., Levi M., McIndoe R. A., Sharma K., Smithies O., Susztak K., Takahashi N., Takahashi T., Animal models of diabetic complications consortium. Mouse models of diabetic nephropathy. Journal of the American Society of Nephrology 2009 20 12 2503 2512
43. Maile L. A., Busby W. H., Gollahon K. A., Flowers W., Garbacik N., Garbacik S., Stewart K., Nichols T., Bellinger D., Patel A., Dunbar P., Medlin M., Clemmons D., Blocking ligand occupancy of the α V β 3 integrin inhibits the development of nephropathy in diabetic pigs. Endocrinology 2014
44. Santulli G., Cipolletta E., Sorriento D., Del Giudice C., Anastasio A., Monaco S., Maione A. S., Condorelli G., Puca A., Trimarco B., Illario M., Iaccarino G., CaMK4 gene deletion induces hypertension. Journal of the American Heart Association 2012 1 4 e001081 10.1161/JAHA.112.001081 2-s2.0-84872681370